NCT02337829 2026-01-08
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Phase 2 Completed
Clinical Trials
6 trialsNCT02966756 2025-12-24
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
AbbVie
Phase 2 Recruiting
NCT03406156 2024-08-06
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
AbbVie
Phase 3 Completed
NCT02980731 2023-02-22
VENICE II
AbbVie
Phase 3 Completed
NCT01889186 2021-12-16
A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion
AbbVie
Phase 2 Completed
NCT00772486 2021-09-22
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
Memgen, Inc.
Phase 1 Completed